Physician profile
Yuval Raizen
NPI 1639339153
$7,006.29
in general payments reported to CMS, 2019-2025
55 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $850 · 2021: $555 · 2022: $924 · 2023: $1,376 · 2024: $1,254 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,572 · Grant: $235 · Education: $60.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,571.81 |
| Grant | $235.20 |
| Education | $60.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $715.48 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $687.36 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $622.24 | 2021-2025 | |
| Janssen Biotech, INC. | $508.68 | 2019-2023 | Imbruvica |
| Celgene Corporation | $360.72 | 2021-2024 | Reblozyl, Pomalyst, Abecma |
| Abbvie INC. | $330.71 | 2022-2025 | |
| Genzyme Corporation | $302.96 | 2019-2023 | |
| Gilead Sciences, INC. | $294.17 | 2021-2024 | Trodelvy |
| Amgen INC. | $260.66 | 2019-2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $216.06 | 2022-2024 | Endopredict |
| Springworks Therapeutics, INC. | $202.77 | 2024-2025 | Ogsiveo, Gomekli |
| Merck Sharp & Dohme LLC | $198.22 | 2019-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $173.29 | 2019-2025 | Venclexta, Itovebi, Tecentriq |
| Astellas Pharma US INC | $125.87 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Exelixis INC. | $121.65 | 2020-2024 | Cabometyx |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuval Raizen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.